Cardio Diagnostics Files Definitive Proxy Statement

TL;DR

CDIO proxy filing out - shareholders vote soon on company matters.

AI Summary

Cardio Diagnostics Holdings, Inc. (CDIO) filed a DEF 14A proxy statement on October 4, 2024, for its fiscal year ending December 31, 2024. The company, formerly known as Mana Capital Acquisition Corp. until June 29, 2021, is based in Chicago, IL. This filing is a definitive proxy statement, indicating it's for shareholder voting purposes.

Why It Matters

This filing is crucial for shareholders as it outlines important information regarding upcoming votes, executive compensation, and corporate governance matters that will shape the company's future direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing (DEF 14A) which is standard for public companies and does not inherently indicate new risks.

Key Players & Entities

• Cardio Diagnostics Holdings, Inc. (company) — Registrant
• Mana Capital Acquisition Corp. (company) — Former company name
• October 4, 2024 (date) — Filing date
• December 31, 2024 (date) — Fiscal year end
• June 29, 2021 (date) — Date of name change

FAQ

Key Financial Figures

• $0.00001 — of the Companys common stock, par value $0.00001 per share (the Common Stock) At the A
• $15,500 — & Co., the solicitation agent, a fee of $15,500, plus disbursements, and will reimburse

Filing Documents

• cdio_def14a.htm (DEF 14A) — 399KB
• image_001.jpg (GRAPHIC) — 5KB
• image_002.jpg (GRAPHIC) — 2KB
• image_003.jpg (GRAPHIC) — 2KB
• image_004.jpg (GRAPHIC) — 5KB
• image_005.jpg (GRAPHIC) — 2KB
• image_006.jpg (GRAPHIC) — 133KB
• image_007.jpg (GRAPHIC) — 127KB
• 0001079973-24-001355.txt ( ) — 782KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 47 Solicitation of Proxies 48 Other Matters and Additional Information 48 CARDIO DIAGNOSTICS HOLDINGS, INC. 311 West Superior Street, Suite 444 Chicago, IL 60654 Telephone: (855) 226-9991 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 15, 2024 PROXY STATEMENT SUMMARY This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board of Directors” or the “Board”) of Cardio Diagnostics Holdings, Inc., a Delaware corporation, for use at the Annual Meeting of Stockholders. This Proxy Statement and related materials are first being made available to stockholders on or about October 4, 2024. References in this Proxy Statement to we, us, our, or the Company refer to Cardio Diagnostics Holdings, Inc. and its consolidated subsidiary, and references to the Annual Meeting are to the 2024 annual meeting of stockholders. This proxy summary highlights information contained elsewhere in this proxy statement and does not contain all of the information that you should consider. You should read the entire proxy statement carefully before voting. Our Annual Meeting Date and Time November 15, 2024 at 11:00 a.m. CST Place Virtually at www.cstproxy.com/cardiodiagnosticsinc/2024 Record Date September 24, 2024 Who Can Vote Only owners of record of the Company’s issued and outstanding common stock as of the close of business on September 24, 2024. Each share of common stock is entitled to one vote. Number of Shares Outstanding as of Record Date 25,905,656 shares of the Companys common stock, par value $0.00001 per share (the Common Stock) At the Annual Meeting, the stockholders of the Company will be asked to vote on the three proposals below. Your vote is ve

View Full Filing

View this DEF 14A filing on SEC EDGAR